SNS01-T: Interim Phase Ib/IIa data

Interim data from 4 patients in the third cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that twice-weekly 0.2 mg IV SNS01-T for 6 weeks led to 3 cases of stable disease at week 3 and 2 cases of stable disease at week 6. Senesco said 1 myeloma patient had reductions in disease-related proteins in the blood and a second patient with DLBCL had evidence of tumor shrinkage in some lesions. SNS01-T was well tolerated with no dose-limiting toxicities (DLTs) reported. The most common adverse events were manageable infusion reactions and platelet count decreases. Data were presented the American Society of Hematology meeting in New Orleans. ...